Phase 2 N=47 Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
Familial Adenomatous Polyposis
Primary: 13-HODE Colonic Tissue Levels — 14.56; 18.83; 23.02; 20.03 ng/mg tissue protein
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=27 A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris
Pemphigus Vulgaris
Primary: Percentage of Participants With Treatment-emergent Adverse Events — 74.1; 86.7; 11.1; 0 percentage of participants
Phase 2 N=13 A Study for Ureter Visualization, Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
Laparoscopic/Minimally Invasive Colorectal Surgery
Primary: Percentage of Participants With Successful Anatomical Visualization of the Index Ureter(s) — 66.7; 100.0; 100.0; 66.7 percentage of participants
Phase 2 N=106 Repeat Quadratus Lumborum Block to Reduce Opioid Need in Patients After Pancreatic Surgery
Pancreatic Carcinoma
Primary: Number of Participants Discharged Opioid-Free — 19; 27 Participants — p=0.17
Phase 2 N=57 The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
HIV Infections
Primary: Geometric Mean Area Under the Plasma Concentration-time Curve Over 24 Hours (AUC0-24h) for ABC, DTG, and 3TC — 17.7; 19.8; 15.1; 17.4 h*ug/mL
Phase 2 N=114 NSAID Effects on Clinical and Imaging Breast Biomarkers
Inflammation · Cancer · Pain
Primary: Change in Breast Density Measured as Fat to Water Ratio by Magnetic Resonance Imaging — -9.8; -3.6 percent change in breast density — p=<0.05
Phase 2 N=42 Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response
Heart Failure
Primary: VO2peak — 17.7; 18.0 mL/kg/min
Phase 2 N=21 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Peak Oxygen Uptake (VO2 Max) at 24 Weeks — 1.28 mL/min/kg
Phase 2 N=6 A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
HER2 Amplified Breast Cancer
Primary: Changes in Colon Pathology — 2; 2 participants
Phase 2 N=266 Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 16 (Intent-to-Treat [ITT] Estimand) — 8.8; -29.7; -44.0; -47.2 Percent…
Phase 2 N=8 Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Endometriosis
Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317
Phase 2 N=64 Rhu-pGSN for Severe Covid-19 Pneumonia
Sars-CoV2
Primary: Efficacy: Proportion of Subjects Alive Not on Vasopressors, Mechanical Ventilator, or Dialysis — 27; 25 participants — p=>0.05
Phase 2 N=39 Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
Neuroendocrine Tumors · Meningioma · Neuroblastoma
Primary: Frequency of Tumor Response at 9 Months After Last Treatment — 0; 1; 19; 15 Participants
Phase 2 N=125 Study of CG100649 Versus Celecoxib in Osteoarthritis Patients
Osteoarthritis
Primary: Change of the WOMAC Pain Subscale at Day 28 From Baseline — -14.33; -12.47; -13.24 units on a scale
Phase 2 N=37 Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Progression Free Survival — 70 percentage of participants with PRS